# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT S0d747c1585
CUTOFF DATE (today): 2022-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S649245107c
CUTOFF DATE (today): 2023-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-03-10 | official-forward (B) | draft_guidance_availability_notice | "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs." This revised draft guidance addresses the verification systems that manufacturers, repa
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance entitled "Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs." This revised draft guidance addresses the verification systems that manufacturers, repackagers, wholesale distributors, and dispensers must have in place to comply with the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Supply Chain Security Act (DSCSA). Specifically, this revised draft guidance covers the statutory verification system requirements that include the quarantine and investigation of a product determined to be suspect and the quarantine and disposition of a product determined to be illegitimate. The revised draft guidance also addresses the statutory requirement for notification to the Agency of a product that has been cleared by a manufacturer, repackager, wholesale distributor, or dispenser (also referred to as "trading partners") after a suspect product investigation because it is determined that the product is not an illegitimate product. Finally, the revised draft guidance addresses the statutory requirement for responding to requ
---
## SNAPSHOT S904f926f33
CUTOFF DATE (today): 2024-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S8f9e3d9370
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S717f3a1702
CUTOFF DATE (today): 2024-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S5f9fb0e546
CUTOFF DATE (today): 2021-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Drug Products Labeled as Homeopathic
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S8546475ab2
CUTOFF DATE (today): 2026-01-01
Regulator: SEBI (IN)
Matter: SEBI consultation: proposed amendments to the certification regime for associated persons in the securities markets
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT S7afc7d0f28
CUTOFF DATE (today): 2026-07-26
Regulator: SEBI (IN)
Matter: SEBI consultation: revising the method for calculating variable net worth of stock brokers
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Se97d4c3825
CUTOFF DATE (today): 2024-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S71ad772de7
CUTOFF DATE (today): 2021-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S1e936a2c0a
CUTOFF DATE (today): 2023-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-11-01 | official-forward (B) | draft_guidance_availability_notice | "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials." The purpose of this draft guidance is to outline the most appropriate methods for measuring a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials." The purpose of this draft guidance is to outline the most appropriate methods for measuring and recording growth and evaluating pubertal development for drugs or biological products in development for pediatric use when such an assessment is necessary to support safety. This draft guidance is intended to encourage a consistent approach to collecting interpretable and accurate growth and pubertal development data. This draft guidance does not address use of growth or pubertal development data to support primary evidence of efficacy in growth disorders and does not address evaluation of nutritional status.
---
## SNAPSHOT Sc8c82d2daa
CUTOFF DATE (today): 2026-07-26
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing the pre-open call auction price-discovery mechanism for IPO listings and re-listed scrips
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-05-21 | official-forward (B) | consultation_paper | "Consultation Paper on Review of price discovery mechanism through Pre-open Call Auction Session for IPO and Re-listed scrips" | www.sebi.gov.in
   Claims: Seeks comments on reviewing the price-discovery mechanism of the Pre-open Call Auction Session used for IPO listings and re-listed scrips. / Describes the existing 60-minute session structure (45 min order entry/modification/cancellation, 10 min matching, 5 min buffer) with random closure between the 35th and 45th minute. / Notes there is currently no price band in this Call Auction Session and that market orders are not allowed. / Frames the review as addressing price-discovery/volatility concerns on the day of listing or re-listing.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals to review the price discovery mechanism through Pre-open Call Auction Session (hereinafter referred as 'Call Auction Session') for IPO and re-listed scrips on the date of their listing or re-listing. A Call Auction Session for IPO and re-listed scrips was introduced by SEBI vide its circular No. CIR/MRD/DP/01/2012 dated January 20, 2012.
---
## SNAPSHOT S4f5a1e7aa0
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-09-23 | official-forward (B) | draft_guidance_availability_notice | "Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency or we) is announcing the availability of a draft guidance for industry #254 entitled "Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products." FDA's Center for Veterinary Medicine (CVM) is issuing this guidance for sponsors, f
   Excerpt: The Food and Drug Administration (FDA or Agency or we) is announcing the availability of a draft guidance for industry #254 entitled "Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products." FDA's Center for Veterinary Medicine (CVM) is issuing this guidance for sponsors, firms, individuals, and establishments that participate in the manufacture of, or perform any aspect of, the donor eligibility determination for animal cells, tissues, and cell- and tissue-based products (ACTPs), which meet the definition of new animal drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Donor eligibility is a critical component of current good manufacturing practices (CGMPs) when manufacturing ACTPs. A donor should be considered eligible to donate ACTPs only if screening of the donor shows that the donor is free from risk factors for, and clinical evidence of, infection with relevant disease agents and diseases, and the donor (and product/source material) test results for relevant disease agents are negative or nonreactive.
---
## SNAPSHOT S4da72de936
CUTOFF DATE (today): 2021-07-01
Regulator: FDA (US)
Matter: FDA draft guidance: Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb5e05d04c0
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2020-04-21 | official-forward (B) | draft_guidance_availability_notice | "Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted Under a Biologics License Application, New Drug Application, or Abbreviated New Drug Application; Draft Guidance for Industry an" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that a
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry and FDA entitled "Technical Considerations for Demonstrating Reliability of Emergency- Use Injectors Submitted under a BLA, NDA or ANDA." For injectable drug or biological products that are intended to treat emergent, life- threatening conditions, it is essential to ensure that the emergency- use injector will reliably deliver the drug or biological product as intended. This is particularly critical for drugs when failure of the injector may prevent adequate delivery of a life-saving drug to a patient. The draft guidance describes the technical considerations for demonstrating reliability of emergency-use injectors under a biologics license application (BLA), new drug application (NDA), or abbreviated new drug application (ANDA).
---
## SNAPSHOT S8e9fa66f8f
CUTOFF DATE (today): 2026-07-26
Regulator: SEBI (IN)
Matter: SEBI consultation: investor consent and conflicted-transaction thresholds for Alternative Investment Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sba6a9f943b
CUTOFF DATE (today): 2026-06-26
Regulator: SEBI (IN)
Matter: SEBI consultation: standardising the process for opening mutual fund folios and executing the first investment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-10-23 | official-forward (B) | consultation_paper | "Consultation Paper on Standardisation of process for Opening of Mutual Fund Folios and Execution of First Investment" | www.sebi.gov.in
   Claims: Proposes that a new mutual fund folio's first transaction/investment be permitted only after KYC verification is completed by the KRA and the folio is marked KYC-compliant. / Notes current practice: AMCs conduct internal KYC checks and process the investment while simultaneously forwarding documents to the KRA, sometimes resulting in KYC non-compliant folios if the KRA, on review, finds deficiencies. / Describes resulting investor impediments, including inability to execute further transactions or receive redemption/dividend proceeds until KYC status is marked compliant in the KRA system.
   Excerpt: The objective of this consultation paper is to solicit comments on the proposed standardization of process for opening of Mutual Fund Folios and execution of first investment. It is proposed that first new folios be ascertained to be fully Know Your Client (KYC) compliant both at the Asset Management Company (AMC) level as well as in the KYC Registration Agency (KRA) system. Investors may commence transactions or investments once the KYC verification is successfully completed by the KRA and the folio is accordingly marked as KYC compliant.
---
## SNAPSHOT S9f383a973f
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb3990dee53
CUTOFF DATE (today): 2022-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S559241d7dd
CUTOFF DATE (today): 2024-01-01
Regulator: FDA (US)
Matter: FDA draft guidance: Benefit-Risk Considerations for Product Quality Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-05-09 | official-forward (B) | draft_guidance_availability_notice | "Benefit-Risk Considerations for Product Quality Assessments; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Benefit- Risk Considerations for Product Quality Assessments." This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessm
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Benefit- Risk Considerations for Product Quality Assessments." This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC) information submitted for FDA assessment as part of original new drug applications (NDAs), original biologics license applications (BLAs), or supplements to such applications, in addition to other information (e.g., inspectional findings) available to FDA during its assessment. This guidance discusses how FDA assesses risks, sources of uncertainty, and possible mitigation strategies for a product quality-related issue and how those considerations inform FDA's understanding of the potential effect on a product. This guidance also discusses how unresolved product quality issues may be addressed in the context of regulatory decision making. The guidance notes that product quality assessments are also done for abbreviated new drug applications (ANDAs), and it discusses how, in certain rare circumstances, unresolved product quality issues m